LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • IR Inquiries
Designated ‘Stem Cell Hair Growth Solution’ research institution by Ministry Commerce, Industry and Energy
2013/12/20
STEM CELL THERAPEUTIC

MEDIPOST has been designated institution which will carry out research projects of Ministry of Commerce, Industry and Energy together with Amore Pacific and Joongang University Hospital and will start R&D of hair growth solution using stem cells.

MEDIPOST announced that it has been selected as the research institution for ‘Bio Medical Instrument Original Technology Development Project’ of latter half of 2013 headed by Korea Evaluation Institute of Industrial Technology under Ministry of Commerce, Industry and Energy.

The research project selected this time is ‘Development of Hair Loss Prevention and Hair Growth Medicine using Protein Produced by Cord Blood which Stimulates Division of Hair Follicle Tissue’ and 3 organizations including MEDIPOST will introduce research capital of KRW2.5 billion with government aid.

Stem cell research is a field where Korea has globally high competitiveness, and in particular because there are almost no effective products in the hair growth field, much attention is being gathered by this research.

In this research, MEDIPOST and Amore Pacific will carry out hair growth optimization of stem cells and development of final product, and Joongang University Hospital research team will carry out mechanism research and pre-clinical/clinical studies.

This research has the goal of development a new concept hair loss treatment drug different to existing products on basis of stem cell treatment drug development experiences of MEDIPOST, and because research results which will support this has been already secured through prior research, a positive result is anticipated.

VIEW LIST

Related News

MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022/07/18
MEDIPOST’s treatment for knee osteoarthritis, enters phase 3 clinical trials in Japan2022/03/25
MEDIPOST’s injectable drug for knee osteoarthritis, SMUP-IA-01, enters phase 2 clinical trials in Korea2021/12/24
MEDIPOST receives approval to proceed with phase 2 clinical trial in Korea for its next-generation injectable drug for knee osteoarthritis, SMUP-IA-012021/10/27

Latest News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award
2022/07/18
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
2022/05/31

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST